Wells Fargo raised the firm’s price target on Cencora (COR) to $429 from $405 and keeps an Overweight rating on the shares. The firm is updating estimates following strong Q1 2026 results. Wells generally sees earnings growth deceleration concerns for U.S. Healthcare as overdone, with “core” EBIT growth modestly above Q1 2025-Q3 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora: OneOncology Acquisition and Conservative Guidance Underscore Upside to $400 Target
- Cencora price target lowered to $420 from $440 at Evercore ISI
- Cencora Earnings Call: Specialty Strength, Guidance Raised
- Cencora Completes OneOncology Acquisition, Lifts Guidance
- Cencora reports Q1 adjusted EPS $4.08, consensus $4.04